Metformin

Quick links to important sections

Metformin

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Metformin

What is Metformin? Overview

As an antihyperglycemic agent, Metformin is the most widely prescribed oral medication globally for managing chronic high blood sugar associated with Type 2 Diabetes. Its composition is the salt form, Metformin Hydrochloride, and it is the sole active member of the Biguanide class currently in clinical use. This status as a primary treatment is established through its long-standing role in clinical practice.


Quick Facts

Property Description
Active ingredient Metformin Hydrochloride
Form Oral tablet (Immediate- and Extended-release)
Pharmacological class Antihyperglycemic agent / Biguanide class
Common use First-line therapy for managing high blood sugar
Origin Synthetic

What Type of Medication is Metformin?

Metformin belongs to the Biguanide class and is recognized as an antihyperglycemic agent, which means its primary function is to lower elevated blood glucose. The drug is considered the first choice for improving blood sugar control in Type 2 Diabetes, provided there are no contraindications. It is chemically known as 1,1-Dimethylbiguanide and is exclusively synthetic in origin, requiring a prescription for dispensing.


Composition, Form, and General Purpose

The medication is composed of the active ingredient Metformin Hydrochloride combined with pharmaceutical excipients and is delivered primarily as an oral tablet. Two popular commercial variations containing the same INN are Glucophage and Glumetza. It is commonly available in two engineered formats: the immediate-release (IR) tablet, which dissolves quickly, and the extended-release (XR) tablet, designed to release the compound slowly over time for sustained effect. The general purpose of taking Metformin is to help establish a more stable blood sugar balance by reducing the excessive glucose released by the liver and enhancing the body's sensitivity to its own insulin. This helps to stabilize the overall metabolic state.

Regulatory References

  1. MedlinePlus Drug Information: Metformin
  2. Long-term effects of Metformin in the Diabetes Prevention Program Outcomes Study (DPPOS)

What side effects are possible with Metformin?

Possible Side Effects and Safety Information

The safety profile of Metformin is officially structured around frequency-classified adverse reactions and key safety constraints, as outlined in government regulatory documents.


Frequency Classification and System-Organ Classes

The most frequent adverse reactions are related to the Gastrointestinal system and are classified as Very Common (ge 1/10), including nausea, vomiting, diarrhea, and abdominal pain. These effects are often most noticeable upon treatment initiation or during dose escalation. A Common (ge 1/100 to < 1/10) adverse effect is taste disturbance (metallic taste).


Serious Adverse Reactions and Safety Constraints

The most serious concern is Lactic Acidosis, which is a Very Rare (< 1/10,000) but severe metabolic complication. This risk is subject to major regulatory warnings and is significantly heightened in patients with Renal Impairment (severely reduced kidney function). Regulatory labels restrict the use of Metformin in these populations, and monitoring of kidney function is required, particularly for Geriatric Patients.

Further safety notes specify that excessive acute or chronic alcohol consumption and intravascular procedures involving iodinated contrast media significantly increase the risk of Lactic Acidosis, necessitating temporary drug discontinuation in the latter scenario. Additionally, long-term exposure is associated with the potential for decreased Vitamin B12 levels, which requires periodic assessment. The risk of Hypoglycemia is a known potential safety concern when Metformin is used in combination with other anti-diabetic agents.

Overdose and Emergency Response

Overdose and When to Seek Help

The most critical and specific manifestation of Metformin overdose, as recognized by regulatory authorities, is the development of Lactic Acidosis, which constitutes a severe and life-threatening metabolic emergency. This acute condition is formally characterized by significantly elevated blood lactate concentrations and a decreased blood pH. The official labeling documents the clinical progression of this outcome.


Documented Manifestations and Outcomes

Presentation Regulatory Finding
Metabolic Risk Lactic Acidosis (most serious outcome) and risk of cardiovascular collapse
Common Symptoms Nausea, vomiting, diarrhea, abdominal pain, and profound malaise
Neurological Signs Somnolence, hypothermia, and potential progression to coma

Required Emergency Actions

Official regulatory guidance mandates that immediate medical attention must be sought if an overdose is suspected or confirmed. Patients must contact emergency services or a poison control center immediately. Urgent help is required at the first sign of overdose or metabolic distress.


Procedural Intervention and Risk Factors

For Metformin overdose complicated by Lactic Acidosis, the essential procedural intervention required to manage the condition and remove accumulated drug is Hemodialysis. Regulatory information explicitly states that no specific antidote is known. Overdose severity is significantly increased in patients with impaired renal function and in the elderly due to reduced drug clearance and resulting accumulation.

Therapeutic Uses of Metformin

What Metformin Treats: Main Uses and Benefits

Metformin is considered a primary oral medication for managing Type 2 Diabetes Mellitus, focusing on stabilizing chronic hyperglycemia. The medication is generally used to manage blood sugar balance and is applied in addressing initial treatment phases when lifestyle changes alone are insufficient. This therapeutic benefit may assist with easing the disruptive symptoms of high blood sugar, such as persistent thirst and frequent urination, thereby contributing to improved long-term metabolic control.


Quick Fact: Relevant for Symptom Clusters related to Systemic Imbalance


Its applications include the management of established Type 2 Diabetes, intervention for Prediabetes to manage the risk of progression, and support for Metabolic Dysfunction in Polycystic Ovary Syndrome (PCOS). By maintaining consistent glucose regulation, its use contributes to improved metabolic control, which may assist with managing the likelihood of long-term systemic functional stress.

“This medication is relevant for easing symptoms related to chronic systemic imbalance and supports general well-being during symptomatic phases.”

For women with PCOS, its use supports stability in the underlying metabolic environment and contributes to managing menstrual cycle regularity. This medicine assists with maintaining functional stability when symptoms of metabolic disorder are more noticeable.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Metformin eligibility is strictly defined by government regulatory agencies based on physiological and demographic criteria, primarily focusing on conditions that increase the risk of lactic acidosis. The medicine is formally allowed for adults and children mathbf10 years and older with Type 2 Diabetes.

Eligibility Status Key Population Rule (Regulatory Basis)
Contraindicated Severe renal impairment (eGFR below 30 mL/min/1.73 m^2).
Contraindicated Acute or chronic metabolic acidosis (including diabetic ketoacidosis), Type 1 Diabetes, severe hepatic impairment, or chronic alcoholism.

The medicine is also contraindicated in acute, unstable conditions that cause tissue hypoxia, such as severe heart failure, shock, or severe infection. Use requires special consideration for other groups. Initiation is not recommended for patients with an eGFR between 30 and 45 mL/min/1.73 m^2. For older adults, renal function must be assessed more frequently. For specific procedures, such as those involving iodinated contrast media or surgery, the medicine must be temporarily discontinued. Use during pregnancy and lactation is generally not recommended.

What should I know about interactions with other medicines?

Metformin Interactions with other medicines and products

The following interaction information is based strictly on official government regulatory documents (e.g., FDA, EMA SmPC) regarding co-administered substances.


Contraindicated Combinations and Procedural Constraints

Metformin co-administration is contraindicated with intravascular iodinated contrast agents used in imaging procedures. Regulatory labels mandate that Metformin must be discontinued prior to, or at the time of, the procedure. It should not be restarted until at least 48 hours after the procedure, and only after renal function has been re-evaluated and found to be normal.


Officially Documented Exposure and Metabolic Interactions

Interactions that reduce Metformin’s renal clearance via Organic Cation Transporter (OCT2) and MATE transporter inhibition can increase systemic exposure. Agents explicitly listed as causing this effect include Cimetidine, Ranolazine, and Dolutegravir.

Co-administration with Carbonic Anhydrase Inhibitors (e.g., Topiramate) and excessive alcohol intake are documented as increasing the risk of lactic acidosis. Agents with intrinsic hyperglycaemic activity (e.g., Glucocorticoids) may require monitoring due to opposing effects on blood sugar control. Furthermore, Metformin may be associated with lower serum Vitamin B12 levels.


Population-Specific Notes

Caution is formally advised for elderly patients and those taking medicines that can acutely impair renal function (e.g., NSAIDs), due to the increased risk of Metformin accumulation.

Mechanism of Action

Metformin modulates glucose homeostasis by influencing three primary mechanistic domains: hepatic glucose output, peripheral glucose utilization, and gastrointestinal glucose absorption.


Suppression of Hepatic Glucose Output

This core mechanism begins in the liver, where Metformin concentrates and acts as a mild inhibitor of Mitochondrial Complex I. This action alters the cellular energy state by raising the AMP:ATP ratio, which triggers the activation of the metabolic sensor AMP-activated protein kinase (AMPK). Activated AMPK then suppresses the enzymes necessary for the liver to produce glucose (gluconeogenesis). This molecular cascade results in a reduction in the amount of glucose released by the liver into the bloodstream.


Enhancement of Peripheral Glucose Use

The compound also influences glucose handling outside the liver, primarily in muscle and fat cells. This is achieved through the activation of AMPK, which facilitates the movement of glucose transporters (GLUT4) to the cell surface. The physiological consequence is an enhanced sensitivity to existing insulin, facilitating muscle tissue glucose clearance from the circulation.


Modulation of Gastrointestinal Absorption

A third, complementary mechanism involves the drug's localized effect within the small intestine. By inhibiting transporters like SGLT1 and other absorption mechanisms, Metformin slows the rate at which dietary glucose enters the bloodstream after a meal. This action influences postprandial glucose dynamics and affects the temporal kinetics of glucose appearance in the systemic circulation.

Dosage and Administration Information

How to Use Metformin

Metformin is administered exclusively via the oral route in either immediate-release (IR) or extended-release (XR) tablet forms, or as an oral solution. Its usage is defined by a structured schedule that dictates both frequency and timing in relation to food intake. The medication is typically used as a long-term therapy.


Dosing and Administration Protocol

The standard adult dosing protocol begins with a low starting dose, such as 500 mg once or twice daily, which is gradually increased (titrated) over several weeks based on tolerance and patient needs. The maximum recommended daily dose for the immediate-release form is generally 2550 mg, taken in divided doses, while the extended-release maximum is 2000 mg once daily.

Administration Rule Specification
Timing with Food IR tablets must be taken with meals; XR tablets are generally taken with the evening meal.
Preparation Extended-release tablets must be swallowed whole and must not be crushed, cut, or chewed.
Missed Dose Do not take a double dose to compensate for a missed dose; resume the usual schedule at the next designated time.

Usage Constraints for Specific Populations

Administration is subject to constraints related to renal function. For adults, use is contraindicated if the estimated Glomerular Filtration Rate (eGFR) is below 30 mL/min/1.73 m^2. For pediatric patients (ages 10 and up), the maximum daily dose is restricted to 2000 mg. Furthermore, the medication must be temporarily discontinued at the time of or prior to any medical procedure involving the use of iodinated contrast agents and withheld for 48 hours afterward.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Metformin

Evidence for Use in Type 2 Diabetes Mellitus

Metformin was studied in contexts exploring blood sugar levels associated with Type 2 Diabetes Mellitus (T2DM). The evidence base includes large-scale, long-term clinical trials (Randomized Controlled Trials) and decades of subsequent observational research. These studies were designed to monitor changes in key glycemic control markers, such as HbA1c (a measure of average blood sugar over several months) and fasting glucose. Beyond blood sugar levels, research also monitored outcomes related to physiological strain or stress, including all-cause mortality, diabetes-related deaths, and major cardiovascular issues, during the defined time intervals.

Studies report how glycemic control markers evolved in the observed populations, particularly those who were overweight or obese, who were followed over extended periods. One key research limitation is that the generalizability of some older data to all current patient profiles, such as those who are not overweight, is not fully established.

Evidence for Use in Prediabetes (Risk Management)

Research examined Metformin in individuals with Prediabetes—a condition where blood sugar levels are elevated but not yet high enough for a T2DM diagnosis. The research was primarily conducted through large, placebo-controlled clinical trials and focused on whether use of the compound was associated with a change in the rate of progression to T2DM diagnosis. Studies monitored outcomes related to metabolic biomarkers, including insulin sensitivity and fasting glucose.

Studies reported that the patterns of progression to T2DM diagnosis were observed differently between the groups receiving Metformin and those receiving a placebo or intensive lifestyle changes during the initial trial periods. Long-term data describing the durability of observations after treatment cessation is limited.

Evidence for Use in Metabolic Dysfunction Related to Polycystic Ovary Syndrome (PCOS)

Metformin was evaluated in women of reproductive age with Polycystic Ovary Syndrome (PCOS). Studies monitored changes in specific outcomes related to systemic or functional imbalance, such as hormonal markers, insulin levels, and menstrual cycle regularity. For this application, evidence quality varies across studies, and many trials had modest sample sizes. Consequently, long-term effects are not fully established.

Key Studies & References Metformin Hydrochloride tablets, USP - Regulatory Monograph (First-Line Therapy Basis)

Frequently Asked Questions (FAQ)

Common questions about Metformin (FAQ)

Q: How long does Metformin stay in your system?

According to official product information, the time it takes for Metformin to be eliminated from the body varies slightly. The half-life in the blood, which is the time it takes for the drug concentration to decrease by half, is approximately 17.6 hours. Following absorption, about 90% of the absorbed medication is eliminated through the kidneys within 24 hours.

Q: Does Metformin damage the kidneys over time?

Official regulatory documents do not state that Metformin itself causes long-term kidney damage. However, the medicine is strictly contraindicated (should not be used) in patients who already have severe renal impairment, or severely reduced kidney function. Regulatory warnings indicate that existing kidney impairment significantly raises the risk of a serious and rare metabolic condition called Lactic Acidosis.

Q: Can older adults safely take Metformin?

Official guidelines note that older adults can take Metformin, but they require special consideration and more frequent monitoring. This caution is advised because Metformin's clearance (how quickly the body removes it) may be reduced due to age-related changes in kidney function. As this could lead to Metformin accumulation, special consideration is required due to the associated increase in the risk of Lactic Acidosis.

Q: Does Metformin cause low blood sugar (hypoglycemia)?

Metformin, when used by itself as a monotherapy, does not typically cause hypoglycemia (abnormally low blood sugar). The risk of developing low blood sugar substantially increases when Metformin is taken in combination with other medications used to treat diabetes, such as insulin or sulfonylureas. Regulatory documents describe the potential for increased risk when Metformin is used in combination with these other agents.

Q: Why is Metformin described as an insulin sensitizer?

The mechanism of action for Metformin includes improving the body's response to the insulin it already produces. It works by increasing the uptake and utilization of glucose in peripheral tissues, such as muscle cells. Because it enhances the body's sensitivity to existing insulin, the drug is commonly described as an insulin sensitizer, although its pharmacological class is Biguanide.

Q: Can Metformin be taken during pregnancy (descriptive question about official advice)?

Regulatory labeling indicates that use of Metformin during pregnancy is not generally recommended. The regulatory labeling generally recommends that Metformin be discontinued upon confirmed pregnancy, and that insulin therapy is typically initiated to maintain blood glucose control. Decisions regarding its use are part of the overall patient care plan.

Q: Does Metformin work immediately after the first pill?

The drug does not have an immediate effect on overall blood sugar control. The concentration of Metformin in the bloodstream stabilizes, or reaches steady-state, within about 24 to 48 hours after starting the medicine. However, the full therapeutic effect on managing long-term blood sugar levels is usually achieved gradually over several weeks.

Q: Is it true that Metformin can help with weight?

Studies examining Metformin for Type 2 Diabetes have often reported that the drug is generally weight-neutral or associated with modest weight loss, in contrast to some other diabetes treatments. The drug is not approved by regulatory bodies as a standalone treatment for weight loss.

Q: Is it normal to feel tired when starting Metformin?

Official prescribing information does not list fatigue or tiredness as a common side effect of Metformin. However, extreme tiredness or unusual weakness can be a serious symptom of the rare metabolic complication called Lactic Acidosis. The presence of extreme fatigue is described in regulatory warnings as a potential signal that requires immediate medical assessment.

Q: Does Metformin affect the results of other lab tests?

Yes, official safety information indicates that long-term Metformin use is associated with a potential decrease in Vitamin B12 serum levels over time. This may require periodic testing of hematological parameters. Additionally, the drug will directly affect the levels of blood lactate and the related ratio, which is monitored when checking for Lactic Acidosis.

Q: Does Metformin have any long-term effects on the heart?

Large-scale clinical trials have monitored cardiovascular outcomes in patients who have taken Metformin for extended periods. While the drug is approved only for blood sugar management, research evidence tracked changes related to major cardiovascular issues in study participants over long time intervals.

Q: Are there alternatives to Metformin for type 2 diabetes?

Metformin belongs to the Biguanide class of medication, which is commonly recommended as a first-line treatment. Official regulatory bodies have approved several other distinct drug classes for Type 2 diabetes, which act through different mechanisms. These include Sulfonylureas, GLP-1 receptor agonists, and DPP-4 inhibitors.

Q: Can Metformin affect fertility in men or women?

Metformin has been studied and used to manage symptoms of Polycystic Ovary Syndrome (PCOS) in women, a condition that can affect menstrual cycle regularity and fertility. For women who become pregnant, studies indicate the drug's use is not expected to increase the background risk for birth defects. Information describing specific fertility effects in men is generally limited in the official regulatory documents.

Q: Does Metformin cause hair loss?

Hair loss is not formally classified as a common or very common adverse reaction in the official prescribing information for Metformin. However, long-term use is associated with decreased Vitamin B12 levels. Severe deficiency of this vitamin may lead to related physiological changes.

Q: Do you need to monitor blood sugar as often if you are on Metformin?

Regulatory documents advise that the patient's progress be checked at regular visits by a healthcare provider. The frequency of at-home self-monitored glucose checks and periodic HbA1c testing is determined by the healthcare team based on the patient's individual treatment plan and overall blood sugar stability.

Q: Can Metformin interact with herbal remedies?

Official safety sources advise that there is generally not enough testing information to confirm that complementary medicines and herbal remedies are safe to take concurrently with Metformin. Official guidance notes that patients should inform their healthcare team about all supplements and herbal products being used, due to the potential for unstudied interactions.

Q: What happens if I take Metformin past its expiration date?

Official regulatory advice strongly recommends against using any medication, including Metformin, beyond its expiration date. Once the expiration date has passed, the drug's labeled safety and efficacy (the guarantee that it will work correctly) cannot be assured. Using expired medication may result in inadequate control of blood glucose.

Q: How does the release mechanism of the extended-release tablet work?

The extended-release (XR) tablet is engineered to release the medication slowly over time. This is often achieved using an osmotic technology, where the tablet core has a specialized coating with tiny exit holes. Once swallowed, water enters the tablet, allowing the dissolved drug to be released in a controlled manner through these ports as it passes through the gastrointestinal tract.

Q: What countries have approved Metformin for diabetes treatment?

Metformin has been widely used and approved for the treatment of Type 2 diabetes for over 50 years in most major global jurisdictions. Regulatory documents frequently refer to its approval in key areas like the United States (FDA), Canada (Health Canada), and the European Union (EMA), indicating its broad international regulatory status.

How should Metformin be stored and disposed of?

How to Store and Dispose of Metformin

Metformin tablets must be stored at Controlled Room Temperature, specifically 20^circC to 25^circC (68^circF to 77^circF), with official labeling permitting brief excursions up to 30^circC. The medication requires protection from moisture and humidity, and its container must be kept tightly closed to maintain product stability. For safety, it is a mandatory requirement to store Metformin out of the sight and reach of children.

Disposal Requirements

Unused or expired Metformin should be discarded according to official regulatory guidelines. The preferred method is using a drug take-back program. If a program is unavailable, follow the specific steps for household trash disposal, which involves mixing the medication with an unappealing substance and sealing it in a bag before disposal. Metformin is not on the official list of medicines approved for flushing down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Metformin found in:

A-Z Index: